Drug Development Research

Top Research Topics at Drug Development Research?

Pharmacology, Internal medicine, Endocrinology, Receptor and Biochemistry are among the topics commonly tackled in the journal. The work on Pharmacology presented in Drug Development Research focuses on Drug in particular. The studies in Internal medicine featured incorporate elements of Biological activity and Cardiology.

It explores research in Endocrinology and the adjacent study of Agonist. The Receptor study tackling the subject of Adenosine receptor is the focus of the journal. Topics in Adenosine were tackled in line with various other fields like Adenosine A1 receptor and Purinergic signalling.

• Pharmacology (33.03%)
• Internal medicine (27.55%)
• Endocrinology (23.96%)

What are the most cited papers published in the journal?

• Some Practical Considerations and Applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen (1217 citations)
• Magnetic nanoparticles for drug delivery (634 citations)
• Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. (505 citations)

Research areas of the most cited articles at Drug Development Research:

The journal publications generally zeroe in on subjects such as Pharmacology, Internal medicine, Endocrinology, Receptor and Biochemistry. The published articles deal with Pharmacology in conjunction with In vivo and similar fields in Biological activity. In addition to Endocrinology research, the published papers aim to explore topics under Agonist and Mechanism of action.

What topics the last edition of the journal is best known for?

• Internal medicine
• Enzyme
• Gene

The previous edition focused in particular on these issues:

The foci of the journal are Pharmacology, Apoptosis, Cancer research, Viability assay and Internal medicine. The study of Pharmacology encompasses disciplines such as Lipopolysaccharide, as well as fields such as Inflammasome, all of which overlap with one another. It holds forums on Apoptosis that merges themes from other disciplines such as Oxidative stress, Western blot and Molecular biology, Flow cytometry.

Drug Development Research addresses concerns in Cancer research which are intertwined with other disciplines, such as Cell, Cancer, Cell growth, Downregulation and upregulation and Gene silencing. The research on Internal medicine featured in Drug Development Research combines topics in other fields like Gastroenterology and Endocrinology. The studies on Drug discussed can also contribute to research in the domains of Clinical trial, Disease and Coronavirus disease 2019 (COVID-19).

The most cited articles from the last journal are:

• Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study. (24 citations)
• Review of registered clinical trials for the treatment of COVID-19. (11 citations)
• Snake venom-derived bradykinin-potentiating peptides: A promising therapy for COVID-19? (10 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Drug Development Research (based on the number of publications) are:

• Harbans Lal (41 papers) absent at the last edition,
• Kenneth A. Jacobson (33 papers) absent at the last edition,
• David Gurwitz (25 papers) published 1 paper at the last edition, 2 less than at the previous edition,
• Frans Awouters (24 papers) absent at the last edition,
• Walter H. Moos (23 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Drug Development Research (based on the number of publications) are:

• Janssen Pharmaceutica (89 papers) absent at the last edition,
• National Institutes of Health (69 papers) published 1 paper at the last edition, 1 less than at the previous edition,
• College of Osteopathic Medicine of the Pacific (58 papers) absent at the last edition,
• Research Triangle Park (48 papers) absent at the last edition,
• Instituto Politécnico Nacional (44 papers) published 3 papers at the last edition the same number as at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 18.35% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 3.88% were posted by at least one author from the top 10 institutions publishing in the journal. Another 0.00% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 0.78% of all publications and 95.35% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.